Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJodi J. LipofMCMatthew ClarkACAlfred Chung

Discussion

Loading...

Member takes

Overview

Reports decreased CAR-T expansion in patients with relapsed/refractory myeloma, indicating prior therapy reduces efficacy and alters immune landscape.

Key Points

  • This research aims to evaluate the impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in myeloma patients.
  • Analyzed peripheral blood mononuclear cells using spectral flow cytometry before and after CAR-T infusion.
  • Compared two groups: anti-BCMA naïve patients and anti-BCMA exposed patients.
  • Statistical comparisons were made using the Mann-Whitney U test to assess differences in CAR-T and T-cell populations.
  • CAR-T expansion was significantly lower in the anti-BCMA exposed group compared to naïve group (median 0.34% vs 13.62%, p=0.04).
  • The anti-BCMA exposed group had fewer non-CAR CD8+ T cells positive for TCF1 and CXCR4 compared to naïve group.
  • After CAR-T therapy, the anti-BCMA exposed group showed higher granzymes B and K expression in CD4+ T cells compared to naive.

Cite This Study

Lipof et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1edhttps://doi.org/10.1182/blood-2025-3916
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy2024 · 14 citations
  2. 2CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025
  3. 3The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  4. 4Sequential BCMA CAR T-cell therapy in refractory multiple myeloma2025 · 12 citations
  5. 5Abstract 3617: Expansion and persistence of anti-BCMA CAR T cells correlates with durability of responses in multiple myeloma patients2024